<p>A) L-DOPA increased H3S28p and H3K27me3S8p in the lesioned striatum that progressively decreased following subsequent administrations (H3S28p: lesion x day interaction: F<sub>(2,25)</sub> = 38.17, p<0.0001; H3K27me3S28p: lesion x day interaction: F<sub>(2,24)</sub> = 11.42, p = 0.0003). *** p<0.001, ** p<0.01, * p<0.05 vs unlesioned hemisphere of the same day. n = 3–6 per condition. Data are means ±S.E.M. B–D) Histograms of differentially expressed transcripts in lesioned striata after chronic L-DOPA compared to acute L-DOPA, from H3K27me3S28p positive and H3K27me3 positive genes (B), from H3K27me3S28p negative but H3K27me3 positive genes (C), and from genes regardless of specific histone marks (D). E) Venn-diagram showing number of gene...
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by d...
L-DOPA is the gold standard treatment for Parkinson’s disease. However, with prolonged use the major...
L-DOPA is the primary pharmacological treatment for relief of the motor symptoms of Parkinson’s dise...
<p>A) Hemiparkinsonian mice were generated by unilateral injection of 6-OHDA into the medial forebra...
Current knowledge of the molecular changes induced by dopamine denervation and subsequent treatment ...
International audienceWe compared for the first time the effects of de novo versus long-term l-Dopa ...
Abstract Motor complications after chronic l-DOPA treatment in patients with Parkinson’s disease may...
International audienceThe therapeutic benefit of L-DOPA is commonly attributed to restoration of dop...
L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of the...
Despite a long-lasting therapeutic use of L-DOPA in Parkinson's disease, doubts still remain concern...
Early gene induction by L-DOPA in the striatum of dopamine denervated rats represents a useful way t...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
The dopamine (DA) precursor L-DOPA remains the most common treatment for Parkinson's disease (PD). H...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
<p>1 µM L-DOPA was added in striatal synaptosomes prepared from at least 70% lesioned striatum and f...
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by d...
L-DOPA is the gold standard treatment for Parkinson’s disease. However, with prolonged use the major...
L-DOPA is the primary pharmacological treatment for relief of the motor symptoms of Parkinson’s dise...
<p>A) Hemiparkinsonian mice were generated by unilateral injection of 6-OHDA into the medial forebra...
Current knowledge of the molecular changes induced by dopamine denervation and subsequent treatment ...
International audienceWe compared for the first time the effects of de novo versus long-term l-Dopa ...
Abstract Motor complications after chronic l-DOPA treatment in patients with Parkinson’s disease may...
International audienceThe therapeutic benefit of L-DOPA is commonly attributed to restoration of dop...
L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of the...
Despite a long-lasting therapeutic use of L-DOPA in Parkinson's disease, doubts still remain concern...
Early gene induction by L-DOPA in the striatum of dopamine denervated rats represents a useful way t...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
The dopamine (DA) precursor L-DOPA remains the most common treatment for Parkinson's disease (PD). H...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
<p>1 µM L-DOPA was added in striatal synaptosomes prepared from at least 70% lesioned striatum and f...
The development of L-DOPA-induced dyskinesia (LID) is attributed to plastic responses triggered by d...
L-DOPA is the gold standard treatment for Parkinson’s disease. However, with prolonged use the major...
L-DOPA is the primary pharmacological treatment for relief of the motor symptoms of Parkinson’s dise...